Table 2.
The prevalence of positive aPL in sera samples from HCPs before and after vaccination (group I), COVID-19 patients hospitalized in the ICU (group II), COVID-19 patients hospitalized in the non-ICU (at three time points: admission, hospital discharge, 3-month follow-up after hospital discharge) (group III), and APS patients (group IV).
| Group I | Group II | Group III | Group IV | ||||
|---|---|---|---|---|---|---|---|
| HCPs (n = 58) |
COVID-19 Patients Hospitalized in ICU (n = 45) |
COVID-19 Patients Hospitalized in Non-ICU (n = 89) |
APS Patients (n = 52) |
||||
| Time Points | Before Vaccination |
After Vaccination * |
During Hospitalization | At Hospital Admission | At Hospital Discharge | 3 Months after Discharge |
|
| aPL | No. of positive (%) | ||||||
| aCL IgG | 0 | 1 (1.7) |
7 (15.6) |
10 (11.2) |
26 (29.2) |
13 (14.6) |
24 (46.2) |
| aCL IgM | 1 (1.7) |
1 (1.7) |
1 (2.2) |
4 (4.5) |
18 (20.2) |
5 (5.6) |
19 (36.5) |
| aCL IgA | 0 | 0 | 0 | 3 (3.4) |
0 | 0 | 1 (1.9) |
| anti-β2GPI IgG | 5 (8.6) |
7 (12.1) |
3 (6.7) |
10 (11.2) |
7 (7.9) |
5 (5.6) |
22 (42.3) |
| anti-β2GPI IgM | 1 (1.7) |
1 (1.7) |
0 | 1 (1.1) |
1 (1.1) |
3 (3.4) |
9 (17.3) |
| anti-β2GPI IgA | 1 (1.7) |
1 (1.7) |
5 (11.1) |
4 (4.5) |
4 (4.5) |
4 (4.5) |
7 (13.5) |
| aPS/PT IgG | 0 | 0 | 1 (2.2) |
0 | 0 | 0 | 22 (42.3) |
| aPS/PT IgM | 0 | 0 | 0 | 5 (5.6) |
5 (5.6) |
3 (3.4) |
19 (36.5) |
| aPS/PT IgA | 0 | 0 | 5 (11.1) |
1 (1.1) |
3 (3.4) |
1 (1.1) |
15 (28.8) |
| at least one positive aPL |
7 (12.1) |
10 (17.2) |
15 (33.3) |
23 (25.8) |
44 (49.4) |
23 (25.8) |
44 (84.6) |
| single aPL positivity ** |
6 (10.3) |
9 (15.5) |
12 (26.7) |
18 (20.2) |
35 (39.3) |
17 (19.1) |
20 (38.5) |
| double aPL positivity ** |
1 (1.7) |
1 (1.7) |
2 (4.4) |
3 (3.4) |
8 (9.0) |
5 (5.6) |
7 (13.5) |
| triple aPL positivity ** |
0 | 0 | 1 (2.2) |
2 (2.2) |
1 (1.1) |
1 (1.1) |
17 (32.7) |
* Values comprise five consecutive tests after vaccination. ** Calculations comprise results of aCL, anti-β2GPI and aPS/PT of all isotypes.